Alba Rocco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7640468/publications.pdf

Version: 2024-02-01

70 papers 3,048 citations

147566 31 h-index 54 g-index

70 all docs

70 docs citations

times ranked

70

4599 citing authors

#	Article	IF	CITATIONS
1	Gut–liver axis: The impact of gut microbiota on non alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 471-476.	1.1	358
2	Alcoholic disease: Liver and beyond. World Journal of Gastroenterology, 2014, 20, 14652.	1.4	173
3	The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract. Alimentary Pharmacology and Therapeutics, 1999, 13, 1429-1436.	1.9	149
4	Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut, 2010, 59, 1465-1470.	6.1	132
5	Helicobacter pylori and molecular events in precancerous gastric lesions. Alimentary Pharmacology and Therapeutics, 2004, 20, 261-270.	1.9	128
6	Effects of long-term PPI treatment on producing bowel symptoms and SIBO. European Journal of Clinical Investigation, 2011, 41, 380-386.	1.7	103
7	Increased mucosal nitric oxide production in ulcerative colitis is mediated in part by the enteroglialâ€derived S100B protein. Neurogastroenterology and Motility, 2009, 21, 1209.	1.6	102
8	Loss of Beta-Catenin Expression in Metastatic Gastric Cancer. Journal of Clinical Oncology, 2003, 21, 1708-1714.	0.8	87
9	Enteric Glial-Derived S100B Protein Stimulates Nitric Oxide Production in Celiac Disease. Gastroenterology, 2007, 133, 918-925.	0.6	86
10	Protective effects of Lactobacillus paracase iF19 in a rat model of oxidative and metabolic hepatic injury. American Journal of Physiology - Renal Physiology, 2010, 299, G669-G676.	1.6	83
11	Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome. BMC Gastroenterology, 2017, 17, 53.	0.8	83
12	Efficacy of 5-Day Levofloxacin-Containing Concomitant Therapy in Eradication of Helicobacter pylori Infection. Gastroenterology, 2012, 143, 55-61.e1.	0.6	81
13	Expression of COX-2, mPGE-synthase1, MDR-1(P-gp), and Bcl-xL: a molecular pathway ofH pylori-related gastric carcinogenesis. Journal of Pathology, 2004, 202, 305-312.	2.1	80
14	A microbiota-centric view of diseases of the upper gastrointestinal tract. The Lancet Gastroenterology and Hepatology, 2017, 2, 298-312.	3.7	77
15	Autoimmune hepatitis following SARS-CoV-2 vaccine: May not be a casuality. Journal of Hepatology, 2021, 75, 728-729.	1.8	72
16	Large Brunner's gland adenoma: Case report and literature review. World Journal of Gastroenterology, 2006, 12, 1966.	1.4	59
17	CD133 and CD44 Cell surface markers do not identify cancer stem cells in primary human gastric tumors. Journal of Cellular Physiology, 2012, 227, 2686-2693.	2.0	59
18	The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma. United European Gastroenterology Journal, 2017, 5, 944-953.	1.6	55

#	Article	IF	Citations
19	The Gut Bacteria-Driven Obesity Development. Digestive Diseases, 2016, 34, 221-229.	0.8	53
20	Diet, <i>H pylori </i> infection and gastric cancer: Evidence and controversies. World Journal of Gastroenterology, 2007, 13, 2901.	1.4	50
21	The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease. International Journal of Molecular Sciences, 2016, 17, 1225.	1.8	50
22	Gastrokine 1 expression in patients with and without Helicobacter pylori infection. Digestive and Liver Disease, 2007, 39, 122-129.	0.4	49
23	Global DNA hypomethylation is an early event in Helicobacter pylori-related gastric carcinogenesis. Journal of Clinical Pathology, 2011, 64, 677-682.	1.0	46
24	<i>Helicobacter pylori</i> and Epigenetic Mechanisms Underlying Gastric Carcinogenesis. Digestive Diseases, 2007, 25, 225-229.	0.8	43
25	Vascular endothelial growth factor and neo-angiogenesis inH. pylori gastritis in humans. Journal of Pathology, 2005, 207, 277-284.	2.1	42
26	Overexpression of chromatin assembly factorâ€1 p60, poly(ADPâ€ribose) polymerase 1 and nestin predicts metastasizing behaviour of oral cancer. Histopathology, 2012, 61, 1089-1105.	1.6	40
27	Reflux oesophagitis in adult coeliac disease: beneficial effect of a gluten free diet. Gut, 2003, 52, 514-517.	6.1	39
28	Gastroduodenal Lesions and Helicobacter pylori Infection in Dyspeptic Patients With and Without Chronic Renal Failure. Helicobacter, 2005, 10, 53-58.	1.6	37
29	Long acting release-octreotide as "rescue―therapy to control angiodysplasia bleeding: A retrospective study of 98 cases. Digestive and Liver Disease, 2014, 46, 688-694.	0.4	36
30	BAG3 protein delocalisation in prostate carcinoma. Tumor Biology, 2010, 31, 461-469.	0.8	34
31	MDR1-P-glycoprotein behaves as an oncofetal protein that promotes cell survival in gastric cancer cells. Laboratory Investigation, 2012, 92, 1407-1418.	1.7	34
32	Cancer stem cell hypothesis and gastric carcinogenesis: Experimental evidence and unsolved questions. World Journal of Gastrointestinal Oncology, 2012, 4, 54.	0.8	31
33	Loss of FHIT protein expression correlates with disease progression and poor differentiation in gastric cancer. Journal of Cancer Research and Clinical Oncology, 2003, 129, 84-88.	1.2	30
34	Vascular Endothelial Growth Factor and Cyclooxygenase-2 are Overexpressed in Ileal Pouch-Anal Anastomosis. Diseases of the Colon and Rectum, 2007, 50, 650-659.	0.7	29
35	Vitamin B12supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. Gut, 2013, 62, 766-773.	6.1	26
36	Tissue ghrelin level and gastric emptying rate in adult patients with celiac disease. Neurogastroenterology and Motility, 2008, 20, 884-890.	1.6	25

#	Article	IF	CITATIONS
37	In Vivo and In Vitro Studies of Cytosolic Phospholipase A2 Expression in Helicobacter pyloriInfection. Infection and Immunity, 2001, 69, 5857-5863.	1.0	23
38	The proliferation marker Chromatin Assembly Factor-1 is of clinical value in predicting the biological behaviour of salivary gland tumours. Oncology Reports, 2011, 25, 13-22.	1.2	22
39	Interleukin-13 mucosal production in Helicobacter pylori-related gastric diseases. Digestive and Liver Disease, 2008, 40, 240-247.	0.4	21
40	Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis. The Lancet Gastroenterology and Hepatology, 2021, 6, 922-932.	3.7	21
41	Up-regulation of heparin binding epidermal growth factor-like growth factor and amphiregulin expression in Helicobacter pylori-infected human gastric mucosa. Digestive and Liver Disease, 2002, 34, 498-505.	0.4	19
42	Chemoprevention of Gastric Cancer: Role of COX-2 Inhibitors and Other Agents. Digestive Diseases, 2004, 22, 320-326.	0.8	19
43	Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms. Pathology Research and Practice, 2008, 204, 163-174.	1.0	18
44	Increased severity of dyspeptic symptoms related to mental stress is associated with sympathetic hyperactivity and enhanced endocrine response in patients with postprandial distress syndrome. Neurogastroenterology and Motility, 2013, 25, 31.	1.6	18
45	Screening for and surveillance of gastric cancer. World Journal of Gastroenterology, 2014, 20, 13681.	1.4	18
46	Incidence and distribution of coeliac disease in Campania (Italy): 2011–2013. United European Gastroenterology Journal, 2015, 3, 182-189.	1.6	17
47	Lactose Intolerance Assessed by Analysis of Genetic Polymorphism, Breath Test and Symptoms in Patients with Inflammatory Bowel Disease. Nutrients, 2021, 13, 1290.	1.7	17
48	Effect of Helicobacter pylori infection on gastric cell proliferation and genomic instablity in a paediatric population of Southern Italy. Digestive and Liver Disease, 2001, 33, 743-749.	0.4	16
49	Pharmacological treatment of gastrointestinal bleeding due to angiodysplasias: A position paper of the Italian Society of Gastroenterology (SIGE). Digestive and Liver Disease, 2018, 50, 542-548.	0.4	15
50	Gastric Emptying Time, Esophageal pH-Impedance Parameters, Quality of Life, and Gastrointestinal Comorbidity in Obese Children and Adolescents. Journal of Pediatrics, 2018, 194, 94-99.	0.9	15
51	Diagnosis of chronic atrophic gastritis by morphometric image analysis. A new method to overcome the confounding effect of the inflammatory infiltrate. Journal of Pathology, 2002, 198, 47-54.	2.1	14
52	13C-Aminopyrine breath test accurately predicts long-term outcome of chronic hepatitis C. Journal of Hepatology, 2012, 56, 782-787.	1.8	14
53	Loss of Expression of Tumor Suppressor p16 ^{INK4} Protein in Human Primary Gastric Cancer Is Related to the Grade of Differentiation. Digestive Diseases, 2002, 20, 102-105.	0.8	11
54	Histological heterogeneity and somatic mtDNA mutations in gastric intraepithelial neoplasia. Modern Pathology, 2008, 21, 733-741.	2.9	11

#	Article	IF	CITATIONS
55	Sweetened carbonated drinks do not alter upper digestive tract physiology in healthy subjects. Neurogastroenterology and Motility, 2008, 20, 780-789.	1.6	11
56	Lactobacillus paracasei F19 versus placebo for the prevention of proton pump inhibitor-induced bowel symptoms: A randomized clinical trial. Digestive and Liver Disease, 2015, 47, 273-279.	0.4	11
57	Gut Microbes and Hepatic Encephalopathy: From the Old Concepts to New Perspectives. Frontiers in Cell and Developmental Biology, 2021, 9, 748253.	1.8	11
58	Treatment Options for Uncomplicated Diverticular Disease of the Colon. Journal of Clinical Gastroenterology, 2009, 43, 803-808.	1.1	10
59	Clinicopathologic Implications of the Epidermal Growth Factor Receptor, Cyclooxygenase 2 Expression, and Human Papillomavirus Status in Squamous Cell Carcinoma of the Uterine Cervix in the Elderly. International Journal of Gynecological Cancer, 2011, 21, 337-348.	1.2	7
60	Gastric Emptying Impacts the Timing of Meal Glucose Peak in Subjects With Uncomplicated Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2269-2276.	1.8	5
61	Probiotics in Gastrointestinal Diseases: All that Glitters Is Not Gold. Digestive Diseases, 2022, 40, 123-132.	0.8	5
62	Pseudopneumoperitoneum in chronic intestinal pseudo-obstruction: A case report. World Journal of Gastroenterology, 2011, 17, 2972.	1.4	5
63	Impact of proton pump inhibitors on cytochrome P450 activity assessed by ¹³ Câ€aminopyrine breath test in patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2021, 53, 608-615.	1.9	4
64	Is Screening for and Surveillance of Atrophic Gastritis Advisable?. Digestive Diseases, 2007, 25, 214-217.	0.8	3
65	Plasma dosage of ghrelin, IGF-1, GLP-Â1 and leptin related to gastric emptying and esophageal pH-impedance in children with obesity. Journal of Endocrinological Investigation, 2021, 44, 1275-1281.	1.8	3
66	Blinded Oral Challenges with Lactose and Placebo Accurately Diagnose Lactose Intolerance: A Real-Life Study. Nutrients, 2021, 13, 1653.	1.7	2
67	An unusual case of high alpha-fetoprotein level and liver masses. Digestive and Liver Disease, 2008, 40, 224.	0.4	1
68	Reply to: "Prediction of liver fibrosis progression by non-invasive tests in chronic hepatitis C: The impact of validation― Journal of Hepatology, 2013, 58, 832.	1.8	0
69	Bone Marrow of Contention: A Rare Case of Recurrent Acute Hepatitis. Digestive Diseases and Sciences, 2021, 66, 408-411.	1.1	0
70	Editorial: proton pump inhibitor use in cirrhosis—a piece of the puzzle. Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 665-666.	1.9	0